TCM
CABA icon

TCG Crossover Management’s Cabaletta Bio CABA Stock Holding History

TCG Crossover Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-86,795
Closed -$132K – 42
2025
Q2 		$132K Hold
86,795
– – 0.02% 37
2025
Q1 		$120K Hold
86,795
– – 0.02% 37
2024
Q4 		$197K Hold
86,795
– – 0.02% 38
2024
Q3 		$410K Hold
86,795
– – 0.03% 36
2024
Q2 		$649K Hold
86,795
– – 0.07% 32
2024
Q1 		$1.48M Sell
86,795
-400,000
-82% -$8.59M 0.12% 33
2023
Q4 		$11.1M Hold
486,795
– – 1.23% 23
2023
Q3 		$7.41M Hold
486,795
– – 1.09% 24
2023
Q2 		$6.28M Hold
486,795
– – 1.03% 19
2023
Q1 		$4.03M Hold
486,795
– – 0.78% 20
2022
Q4 		$4.5M Buy
+486,795
New +$1.77M 0.79% 19

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Superstring Capital Management New York $158M AUM 418.32% 1-Year Est. Return

TCG Crossover Management's CABA Position: Q3 2025 in Review

TCG Crossover Management sold out of Cabaletta Bio (CABA) in Q3 2025, closing a stake of 86,795 shares — an estimated $132K sold.

TCG Crossover Management first reported a position in CABA in Q4 2022 and held it in 11 quarters. The position peaked at $11.1M in Q4 2023. 75 funds tracked by Wall St. Rank hold CABA as of Q3 2025.

  • TCG Crossover Management reported no remaining Cabaletta Bio position as of Q3 2025 after selling out during the quarter.
  • TCG Crossover Management sold 86,795 Cabaletta Bio shares in Q3 2025, an estimated $132K.
  • TCG Crossover Management first reported a position in Cabaletta Bio in Q4 2022 and held it in 11 quarters.
  • TCG Crossover Management's Cabaletta Bio position peaked at $11.1M in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2025.

Based on TCG Crossover Management's 13F filing for Q3 2025, filed 17 Nov 2025.